데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
114084-78-5CCCCCN(C)CCC([OH2+])(P(=O)([O-])O)P(=O)(O)OMPBVHIBUJCELCL-UHFFFAOYSA-N114084-78-5White Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요This third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.
용도A biphosphonate bone resorption inhibitor.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…